BRAF and neoplasm: Considering that patients who have the BRAFV600E mutation maintain disease progression or rapidly develop resistance upon treatment with BRAF inhibitors, at least a proportion of cells within the tumour maintain intrinsic resistance mechanisms [17,34,63].